Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NSAIDs withdrawal in axial spondyloarthritis remission
NCT03425812Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Feb 2018
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of caffeine in axial spondyloarthritis (axSpA) (2 arms), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Percentage of participants with Ankylosing Spondylitis Disease Activity Score (ASDAS) active disease at Week 24. Started Feb 2018; status: recruiting.
02
Drugs
caffeine
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT03425812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03425812.